11:41:19 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-11-11 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-04 Kvartalsrapport 2023-Q1
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-09-27 Extra Bolagsstämma 2022
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Kvartalsrapport 2021-Q1
2021-05-05 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Kvartalsrapport 2020-Q1
2020-05-20 Årsstämma 2020

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamma inom medicinteknik. Bolaget är specialiserade inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2022-11-18 13:42:46

Today, Qlife announces that a delay in finalizing the development of the two-in-one test for influenza and SARS-CoV-2 virus assay, and associated technical adjustment in the Egoo optics, means that this project has been put on hold. The implications of the development delay are that the clinical trial cannot be finalized before end of 2022, which in turn means that the 3[rd] payment will be cancelled by FIND under the project terms.

In December 2021, Qlife signed an agreement with FIND for $ 3.45 million for a 12-month project with the goal of developing a new and cost-effective two-in-one test for influenza and SARS-CoV-2 virus detection in decentralized care environments in low- and middle-income countries (LMIC). Funding to date has been paid out in two milestone payments amounting to 2.55 MUSD.

To move into the next phase, i.e., initiate clinical studies, the assay must have reached design freeze and technical adjustments must have been made to the optics. Due to delays within these developments, it is no longer possible to finalize within the current timeframe ending December 2022.

Qlife is in close dialogue with FIND to clarify whether the last milestone of 0.9 MUSD can be paid-out upon completion in 2023 instead. Until further funding is secured, Qlife has decided to put the project on hold.

"Both FIND and Qlife have a solid interest in bringing the product to the market, particularly in the LMIC, as a future platform for decentralized testing for respiratory diseases. However, in the current financial situation, Qlife is only able proceed with projects with a clear financing plan and a sustainable roadmap that goes beyond the development and regulatory stages. We need to focus our human and financial resources. As a result, we have now decided to await new financing until we can complete the last milestone ", says Thomas Warthoe, CEO of Qlife.